← Back to Clinical Trials
Recruiting NCT07298135

NCT07298135 A Study to Evaluate the Effects of a Prebiotic Soda on Glycemic Control in Adults

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07298135
Status Recruiting
Phase
Sponsor Olipop, PBC
Condition Blood Glucose Control
Study Type INTERVENTIONAL
Enrollment 224 participants
Start Date 2025-12-17
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age 30 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
Prebiotic SodaActive Control

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 224 participants in total. It began in 2025-12-17 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The main objective of this study is to evaluate the chronic effects of replacing traditional non-diet soda with a prebiotic soda on biomarkers associated with glycemic control in adults with glucose dysregulation who are habitual consumers of traditional soda.

Eligibility Criteria

Inclusion Criteria: * Able to provide informed consent * Willing to comply with all study procedures * Male or female, ages 30 - 70 years old * Habitual consumers of traditional non-diet soda (average intake 2 - 3 servings (24-36 fl. oz)/daily in a typical month, representing usual dietary pattern) * BMI between 25 - 35 kg/m² * Fasting plasma glucose between 100 - 125 mg/dL or hemoglobin A1c between 5.7% - 6.4% * Low habitual dietary fiber intake, assessed using a qualitative fiber intake screening questionnaire administered at pre-screening * Willing to maintain stable tobacco/nicotine use habits established for ≥ 90 days, with no initiation, cessation, or change in frequency during the study period * Willing to maintain stable marijuana, hemp, and CBD product use habits established for ≥ 60 days, with no initiation, cessation, or change in frequency during the study period * Willing to maintain habitual diet (with the exception of study products) and physical activity patterns throughout the trial Exclusion Criteria: * Inability to consume a standard 12 fl. oz. carbonated beverage twice daily * Currently engaged or planning to be on an intensive weight loss regimen program * Extreme dietary habits in the judgement of the Investigator or has been diagnosed with an eating disorder * Habitual use of fiber supplements, inulin-based supplements, acacia fiber, glucomannan, prebiotic supplements, or probiotic supplements within 30 days of study enrollment * Known allergy or sensitivity to any of the ingredients in the study products * History or presence of uncontrolled and/or clinically important medical conditions that could interfere with study results interpretation (i.e., diabetes mellitus, CKD stage 4-5, severe liver disease/cirrhosis, uncontrolled hypertension, recent myocardial infarction or stroke (within 6 months), severe mental illness or cognitive impairment, immunodeficiency disorders, active infections). * Gastrointestinal conditions that could potentially interfere with absorption of the study product (i.e., IBD, celiac disease, short bowel syndrome, chronic pancreatitis, gastroparesis, active peptic ulcer disease, gastric bypass or other bariatric surgeries, severe IBS, chronic diarrhea or malabsorption syndromes, active diverticulitis) * Use of oral or injectable steroids within 90 days of enrollment * Use of antibiotic therapy within 90 days of enrollment * Unstable use of prescription medications within 90 days of enrollment that affect plasma glucose levels (e.g., corticosteroids, thiazide diuretics, beta-blockers (some types), antipsychotics, tacrolimus, protease inhibitors, ACE inhibitors) * Use of any of the following prescription medications within 90 days of enrollment: Metformin, sulfonylureas, GLP-1 agonists, SGLT-2 inhibitors, insulin. * History or presence of cancer, except non-melanoma skin cancer, within 2 years of enrollment * Exposure to any non-registered drug product or participation in another intervention study within 30 days prior to enrollment * Recent history (within 12 months) of alcohol or substance abuse * History of major trauma or surgical event within 60 days of enrollment * Person who is pregnant, planning pregnancy, or lactating * Any condition the Investigator believes would interfere with study participation or compliance * Consumption of more than 5 prebiotic sodas within the last 30 days prior to enrollment * Heavy smoker as defined as smoking 20 or more cigarettes per day, or smoked roughly 1 pack a day for 20+ years (more than 20 pack years)

Contact & Investigator

Central Contact

Frequently Asked Questions

Who can join the NCT07298135 clinical trial?

This trial is open to participants of all sexes, aged 30 Years or older, up to 70 Years, studying Blood Glucose Control. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07298135 currently recruiting?

Yes, NCT07298135 is actively recruiting participants. Contact the research team at megha@peoplescience.health for enrollment information.

Where is the NCT07298135 trial being conducted?

This trial is being conducted at Los Angeles, United States.

Who is sponsoring the NCT07298135 clinical trial?

NCT07298135 is sponsored by Olipop, PBC. The trial plans to enroll 224 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology